| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.028 | 0.3 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.3 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.4 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | 0.13 | 0.4 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.055 | 0.4 |
| mRNA | methylstat | CTRPv2 | pan-cancer | AAC | 0.037 | 0.4 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |